207 related articles for article (PubMed ID: 34202667)
1. The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD).
Maciejewska-Markiewicz D; Stachowska E; Hawryłkowicz V; Stachowska L; Prowans P
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34202667
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View.
Valenzuela R; Videla LA
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32075238
[TBL] [Abstract][Full Text] [Related]
3. Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women.
Oya J; Nakagami T; Sasaki S; Jimba S; Murakami K; Kasahara T; Wasada T; Sekiguchi H; Hasegawa M; Endo Y; Iwamoto Y
Eur J Clin Nutr; 2010 Oct; 64(10):1179-85. PubMed ID: 20683463
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
5. Anti-steatotic effects of an n-3 LCPUFA and extra virgin olive oil mixture in the liver of mice subjected to high-fat diet.
Valenzuela R; Espinosa A; Llanos P; Hernandez-Rodas MC; Barrera C; Vergara D; Romero N; Pérez F; Ruz M; Videla LA
Food Funct; 2016 Jan; 7(1):140-50. PubMed ID: 26471014
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN).
Tobin D; Brevik-Andersen M; Qin Y; Innes JK; Calder PC
Nutrients; 2018 Aug; 10(8):. PubMed ID: 30127297
[TBL] [Abstract][Full Text] [Related]
8. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins.
González-Périz A; Horrillo R; Ferré N; Gronert K; Dong B; Morán-Salvador E; Titos E; Martínez-Clemente M; López-Parra M; Arroyo V; Clària J
FASEB J; 2009 Jun; 23(6):1946-57. PubMed ID: 19211925
[TBL] [Abstract][Full Text] [Related]
9. Dietary DHA/EPA Ratio Changes Fatty Acid Composition and Attenuates Diet-Induced Accumulation of Lipid in the Liver of ApoE
Liu L; Hu Q; Wu H; Wang X; Gao C; Chen G; Yao P; Gong Z
Oxid Med Cell Longev; 2018; 2018():6256802. PubMed ID: 30538803
[TBL] [Abstract][Full Text] [Related]
10. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.
Hodson L; Bhatia L; Scorletti E; Smith DE; Jackson NC; Shojaee-Moradie F; Umpleby M; Calder PC; Byrne CD
Eur J Clin Nutr; 2017 Aug; 71(8):973-979. PubMed ID: 28294174
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease.
Musa-Veloso K; Venditti C; Lee HY; Darch M; Floyd S; West S; Simon R
Nutr Rev; 2018 Aug; 76(8):581-602. PubMed ID: 29917092
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E; Byrne CD
Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
[TBL] [Abstract][Full Text] [Related]
13. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
Jump DB; Depner CM; Tripathy S; Lytle KA
Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
[TBL] [Abstract][Full Text] [Related]
14. A defect in the activities of Δ and Δ desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease.
Das UN
World J Diabetes; 2011 Nov; 2(11):176-88. PubMed ID: 22087354
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials.
Guo XF; Yang B; Tang J; Li D
Clin Nutr; 2018 Feb; 37(1):113-122. PubMed ID: 28161092
[TBL] [Abstract][Full Text] [Related]
16. Accretion of Dietary Docosahexaenoic Acid in Mouse Tissues Did Not Differ between Its Purified Phospholipid and Triacylglycerol Forms.
Adkins Y; Laugero KD; Mackey B; Kelley DS
Lipids; 2019 Jan; 54(1):25-37. PubMed ID: 30697752
[TBL] [Abstract][Full Text] [Related]
17. Dietary Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) Operate by Different Mechanisms to Modulate Hepatic Steatosis and Hyperinsulemia in
Hong L; Zahradka P; Cordero-Monroy L; Wright B; Taylor CG
Nutrients; 2019 Apr; 11(4):. PubMed ID: 31022865
[TBL] [Abstract][Full Text] [Related]
18. Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease.
Calder PC
Curr Opin Clin Nutr Metab Care; 2022 Jul; 25(4):248-255. PubMed ID: 35762160
[TBL] [Abstract][Full Text] [Related]
19. Novel chemical mediators in the resolution of inflammation: resolvins and protectins.
Serhan CN
Anesthesiol Clin; 2006 Jun; 24(2):341-64. PubMed ID: 16927933
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid facts, Part III: Cardiovascular disease, or, a fish diet is not fishy.
Pauwels EK; Kostkiewicz M
Drug News Perspect; 2008 Dec; 21(10):552-61. PubMed ID: 19221636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
